Browse

BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers

DC Field Value Language
dc.contributor.authorLee, Yoo-kyung-
dc.contributor.authorChoi, Eunhee-
dc.contributor.authorKim, Min A-
dc.contributor.authorPark, Pil-gu-
dc.contributor.authorPark, Noh-hyun-
dc.contributor.authorLee, Hyunsook-
dc.date.accessioned2010-06-08T04:47:05Z-
dc.date.available2010-06-08T04:47:05Z-
dc.date.issued2009-08-04-
dc.identifier.citationBritish Journal of Cancer 101: 504 – 510en
dc.identifier.issn0007-0920-
dc.identifier.urihttps://hdl.handle.net/10371/67628-
dc.description.abstractBACKGROUND: Epithelial ovarian cancer is one of the most lethal malignancies, and has a high recurrence rate. Thus, prognostic markers
for recurrence are crucial for the care of ovarian cancer. As ovarian cancers frequently exhibit chromosome instability, we aimed at
assessing the prognostic significance of two key mitotic kinases, BubR1 and Aurora A.
METHODS: We analysed paraffin-embedded tissue sections from 160 ovarian cancer patients whose clinical outcomes had been
tracked after first-line treatment.
RESULTS: The median recurrence-free survival in patients with a positive and negative expression of BubR1 was 27 and 83 months,
respectively (Po0.001). A positive BubR1 expression was also associated with advanced stage, serous histology and high grade.
In contrast, Aurora A immunostaining did not correlate with any of the clinical parameters analysed.
CONCLUSION: BubR1, but not Aurora A, is a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers.
en
dc.description.sponsorshipResearch in the H Lee laboratory is funded by the National
Research Laboratory Program from the Korean ministry of
Education and Science (ROA-2008-000-20023-0). This work was
also supported by the Seoul National University Hospital Grant
(0420080450), the 21C Frontier Functional Genome Project (FG06-
2-14) of the Korean ministry of Education and Science, Korea
Research Foundation (KRF-2005-C00097), and the National R&D
Program for Cancer Control (0620070) from the Korean ministry
of Health welfare and Family Affairs. Imaging facilities in the H Lee
laboratory are funded by RCFC (R11-2005-009-04003-0) of the SRC
program from KOSEF.
en
dc.language.isoenen
dc.publisherNature Publishing Groupen
dc.subjectBubR1en
dc.subjectAurora Aen
dc.subjectovarian neoplasmen
dc.subjectprognosisen
dc.subjectrecurrence-free survivalen
dc.titleBubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancersen
dc.typeArticleen
dc.contributor.AlternativeAuthor이유경-
dc.contributor.AlternativeAuthor최은희-
dc.contributor.AlternativeAuthor김민아-
dc.contributor.AlternativeAuthor박필구-
dc.contributor.AlternativeAuthor박노현-
dc.contributor.AlternativeAuthor이현숙-
dc.identifier.doi10.1038/sj.bjc.6605161-
Appears in Collections:
College of Natural Sciences (자연과학대학)Dept. of Biological Sciences (생명과학부)Journal Papers (저널논문_생명과학부)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse